Former AdventHealth President/CEO Terry Shaw Joins Clearsense Board of Directors

Veteran health system leader brings four decades of experience to help Clearsense empower healthcare organizations to unlock cost savings and drive innovation through data revitalization

NASHVILLE, Tenn., July 17, 2025 /PRNewswire/ — Clearsense®, a cloud-based data enablement platform company, is proud to announce the appointment of veteran health system leader, Terry Shaw, to its board of directors.

Shaw recently retired as President and CEO of AdventHealth—one of the nation’s largest not-for-profit health systems. During his 40-year tenure, he helped shape the organization into a national leader, overseeing more than 50 hospital campuses, 2,000+ care sites, and 100,000+ team members. He led AdventHealth through significant digital transformation, financial strengthening, and mission-centered growth.

Under Shaw’s leadership, AdventHealth developed a cutting-edge technology ecosystem to support both clinical and operational excellence. His focus on quality, innovation, and fiscal responsibility has earned him national recognition, including his recent inclusion in Modern Healthcare’s 100 Most Influential People in Healthcare.

“We are incredibly grateful to welcome someone of Terry’s caliber to our board,” said Jason Z. Rose, CEO of Clearsense. “Over four decades, he has demonstrated extraordinary leadership across mission, strategy, operations, clinical innovation, and finance. His wisdom, guidance, and vision will be invaluable as we continue helping health systems reduce costs and unlock the full value of their data to fuel innovation and improve outcomes.”

Shaw’s deep understanding of healthcare finance, technology investment, and long-range planning makes him a powerful addition to the Clearsense board at a time when hospitals are under mounting pressure to reduce expenses while accelerating innovation. As M&A activity begins to rebound across the industry, health systems are seeking strategic ways to unlock the value of their data, streamline operations, and retire redundant IT systems—including so-called “Zombie Apps” that silently drain budgets, duplicate functionality, and increase cybersecurity risk.

“Now more than ever, it’s critical for healthcare organizations to reduce waste and streamline access to timely, trusted data that supports clinical care, operational decisions, and innovation,” said Terry Shaw. “Clearsense is delivering exactly that—empowering health systems to reduce unnecessary costs, retire outdated systems that present risk, and innovate more effectively. I’m honored to join the board and contribute to a company that’s truly transforming how healthcare leaders manage their P&L and use their data.”

About Clearsense
Clearsense is revitalizing healthcare data with its innovative approach. Its 1Clearsense data enablement platform is a cutting-edge, cloud-native solution that integrates advanced tools and technologies. This platform empowers healthcare organizations to swiftly and seamlessly access data from diverse sources, when and where it’s needed. Clearsense’s solutions have garnered adoption across a spectrum of healthcare institutions, including large integrated delivery networks, health systems, regional hospitals, academic medical research centers, payors and life sciences. By enabling digital information, Clearsense drives unparalleled value, fostering innovation, streamlining operations, enhancing care quality, and generating substantial cost savings. Learn more at clearsense.com.

Media Contact:

Andrea LePain
eMedia Junction
andrea@emediajunction.com
617-894-1153

View original content to download multimedia:https://www.prnewswire.com/news-releases/former-adventhealth-presidentceo-terry-shaw-joins-clearsense-board-of-directors-302507242.html

SOURCE Clearsense

Staff

Recent Posts

AMEEREX Signs MOU to Acquire 45.6 million-Ounce Silver-Gold Project in Nevada, Expanding Its North American Precious-Metals Portfolio

ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…

24 minutes ago

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…

6 hours ago